[go: up one dir, main page]

Follow
Reed F Beall
Title
Cited by
Cited by
Year
Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis
R Beall, R Kuhn
PLoS medicine 9 (1), e1001154, 2012
2102012
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997
B Sahragardjoonegani, RF Beall, AS Kesselheim, A Hollis
Journal of pharmaceutical policy and practice 14 (1), 3, 2021
702021
Evaluating the impact of the Orphan Drug Act’s seven-year market exclusivity period
A Sarpatwari, RF Beall, A Abdurrob, M He, AS Kesselheim
Health Affairs 37 (5), 732-737, 2018
662018
Is patent “evergreening” restricting access to medicine/device combination products?
RF Beall, JW Nickerson, WA Kaplan, A Attaran
PLoS One 11 (2), e0148939, 2016
582016
Patents and regulatory exclusivities on GLP-1 receptor agonists
R Alhiary, AS Kesselheim, S Gabriele, RF Beall, SS Tu, WB Feldman
Jama 330 (7), 650-657, 2023
562023
Pre-market development times for biologic versus small-molecule drugs
RF Beall, TJ Hwang, AS Kesselheim
Nature Biotechnology 37 (7), 708-711, 2019
512019
Patents and regulatory exclusivities on inhalers for asthma and COPD, 1986–2020: study examines patents and regulatory exclusivities on inhalers for asthma and COPD from 1986 …
WB Feldman, D Bloomfield, RF Beall, AS Kesselheim
Health Affairs 41 (6), 787-796, 2022
402022
A method for approximating future entry of generic drugs
RF Beall, JJ Darrow, AS Kesselheim
Value in Health 21 (12), 1382-1389, 2018
362018
Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement
RF Beall, R Kuhn, A Attaran
Health Affairs 34 (3), 493-501, 2015
362015
Modes of delivery in preventive intervention studies: a rapid review
RF Beall, N Baskerville, M Golfam, S Saeed, J Little
European journal of clinical investigation 44 (7), 688-696, 2014
362014
Patent term restoration for top-selling drugs in the United States
RF Beall, JJ Darrow, AS Kesselheim
Drug Discovery Today 24 (1), 20-25, 2019
342019
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
SM Baxi, R Beall, J Yang, TK Mackey
Globalization and Health 15 (1), 57, 2019
302019
Tertiary patenting on drug–device combination products in the United States
RF Beall, AS Kesselheim
Nature Biotechnology 36 (2), 142-145, 2018
292018
COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022
B Lau, M Tadrous, C Chu, L Hardcastle, RF Beall
Cmaj 194 (23), E801-E806, 2022
282022
The characteristics of patents impacting availability of biosimilars
VL Van de Wiele, RF Beall, AS Kesselheim, A Sarpatwari
Nature Biotechnology 40 (1), 22-25, 2022
262022
The global intellectual property ecosystem for insulin and its public health implications: an observational study
WA Kaplan, RF Beall
Journal of Pharmaceutical Policy and Practice 10 (1), 3, 2017
232017
Differential legal protections for biologics vs small-molecule drugs in the US
OJ Wouters, M Vogel, WB Feldman, RF Beall, AS Kesselheim, SS Tu
JAMA 332 (24), 2101-2108, 2024
212024
First‐line pharmacotherapy for incident type 2 diabetes: prescription patterns, adherence and associated costs
DJT Campbell, DB Campbell, Y Ogundeji, F Au, R Beall, PE Ronksley, ...
Diabetic Medicine 38 (9), e14622, 2021
212021
Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation
A Fichadiya, A Quinn, F Au, D Campbell, D Lau, P Ronksley, R Beall, ...
Europace 26 (3), euae054, 2024
192024
Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines
RF Beall, JW Nickerson, A Attaran
Open Medicine 8 (4), e130, 2014
192014
The system can't perform the operation now. Try again later.
Articles 1–20